3Pelclova D, Bartunkova J, Fenclova Z, et al. Asbestos exposure and antineutrophil cytoplasmic Antibody (ANCA) positivity [J]. Arch Environ Health, 2003, 58(10): 662-668.
4Weidanz F, Day CJ, Hewins P, et al. Recurrences and infections during ontinuous tmmunosuppressive therapy after begSnning dialysis in ANCA-associated vasculitis [J]. Am J Kidney Dis, 2007, 50(1): 36-46.
5Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consen- sus conference [J]. Arthritis Rheumatism, 1994, 37 ( 2 ) : 187-192.
6Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplas- mic antibodies and associated diseases: a review of the clinical and laboratory features[-J]. Kidney Int, 2000,57 (3):846 -862.
7Smith K ,Jones R,Burns S,et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythe- matosus and vasculitis: Remission, relapse, and re-treat- ment[J]. Arthritis Rhedm, 2006,54(9) : 2970-2982.
8Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyelophosphamide for ANCA-assoeiated vasculitis[J]. NEngl J Med,2010,363(3) :221-232.
9Cartin-Ceba R, Fervenza FC, Specks U. Treatment of an- tineutrophil cytoplasmic antibody-associated vasculitis with rituximab[J]. Curt Opin Rheumatol, 2012,24 ( 1 ) : 15-23.
10Laurino S,Chaudhry A, Booth A, et al. Prospective study of TNFa blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement [J]. Nephrol Dial Transplant, 2010,25 (10) : 3307-3314.
